<DOC>
	<DOCNO>NCT02229890</DOCNO>
	<brief_summary>Study evaluate safety efficacy intravenous recombinant tissue Plasminogen Activator , alteplase , Actilyse® ( rt-PA ) ( 0.9 mg/kg ) within 3 hour symptom onset acute ischemic stroke</brief_summary>
	<brief_title>An International Observational Study Safety Efficacy Thrombolysis Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Female male inpatient Age 18 80 year Clinical diagnosis ischemic stroke cause measurable neurological deficit define impairment language , motor function , cognition , gaze , vision and/or neglect . Ischemic stroke defined event characterize sudden onset acute focal neurological deficit , presume caused cerebral ischemia , CT scan exclusion hemorrhage Onset symptom within 3 hour prior initiation thrombolysis treatment Stroke symptom present least 30 minute significantly improve treatment . Symptoms must distinguishable episode generalize ischemia ( i.e . syncope ) , seizure , migraine disorder Patients willing receive thrombolysis treatment give inform consent regard retrieval storage data follow procedure , accord regulation participate country Willingness ability comply observational study protocol Evidence intracranial hemorrhage ( ICH ) CTscan . Symptoms ischemic attack begin 3 hour prior infusion start time symptom onset unknown Symptoms acute ischemic stroke either rapidly improve minor start infusion Severe stroke assess clinically and/or appropriate imaging technique Seizure onset stroke History previous stroke serious headtrauma within three month Administration heparin within previous 48 hour precede onset stroke elevate activated thromboplastin time ( aPTT ) presentation A combination previous stroke concomitant diabetes Platelet count 100,000/mm³ Systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg , aggressive management ( repeat IV medication ) necessary reduce BP limit . Blood glucose &lt; 50 &gt; 400 mg/dl Significant bleeding disorder present within past 6 month , know hemorrhagic diathesis Patients receive oral anticoagulant , e.g . warfarin sodium ( INR &gt; 1.3 ) History evidence suspicion intracranial hemorrhage include subarachnoid hemorrhage Severe uncontrolled arterial hypertension Any history central nervous system damage ( i.e . neoplasm , aneurysm , intracranial spinal surgery ) Hemorrhagic retinopathy , e.g . diabetes ( vision disturbance may indicate hemorrhagic retinopathy ) hemorrhagic ophthalmic condition Bacterial endocarditis , pericarditis Prolonged traumatic cardiopulmonary resuscitation ( &gt; 2 minute ) , obstetrical delivery within past 10 day , recent puncture noncompressible bloodvessel ( e.g . subclavian jugular vein puncture ) Acute pancreatitis Documented ulcerative gastrointestinal disease last 3 month Arterial aneurysm , arterial/venous malformation Neoplasm increase bleed risk Severe hepatic dysfunction , include hepatic failure , cirrhosis , portal hypertension ( oesophageal varix ) active hepatitis Major surgery significant trauma past 10 day ( include trauma associate current acute myocardial infarction ) , recent trauma head cranium Hypersensitivity active substance alteplase excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>